PTC Therapeutics (NASDAQ:PTCT) Given Overweight Rating at Morgan Stanley
Morgan Stanley restated their overweight rating on shares of PTC Therapeutics (NASDAQ:PTCT – Free Report) in a research note issued to investors on Friday,Benzinga reports. They currently have a $70.00 price objective on the biopharmaceutical company’s stock, up from their prior price objective of $67.00. Other equities research analysts have also issued research reports about […]
Morgan Stanley restated their overweight rating on shares of PTC Therapeutics (NASDAQ:PTCT – Free Report) in a research note issued to investors on Friday,Benzinga reports. They currently have a $70.00 price objective on the biopharmaceutical company’s stock, up from their prior price objective of $67.00. Other equities research analysts have also issued research reports about […]
